World-first vaccine for melanoma cuts risk of death in half, trial finds
Source: 9News, June 2024
A world-first personalised vaccine for melanoma vaccine has been found to reduce the risk of cancer reoccurrence or death by 49 per cent over three years.
The results of the vaccine trial is offering fresh hope in the fight against skin cancer and are being presented at the 2024 American Society of Clinical Oncology annual meeting.
The vaccine, called mRNA-4157 (V940), was developed by Moderna and was given to patients in the trial in combination with an immunotherapy drug called Keytruda.